Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Luye Pharma Group Ltd. (LYPHF)
Yantai, CN
Luye Pharma Group Ltd., serving as an investment holding company, engages in the global research, development, production, commercialization, and distribution of a diverse portfolio of pharmaceutical products. Their oncology treatments include Lipusu, indicated for ovarian and breast cancer; CMNa, a chemical sensitizer used in cancer radiotherapy; Tiandida, targeting ovarian or non-small cell lung cancer; and Boyounuo, an injection addressing various cancers and solid tumors. The company also provides Tiandixin, an adjuvant therapy for malignant tumors, hydrothorax, ascites, and respiratory infections; Yitaida, for acute promyelocytic leukemia and liver cancer; and Lutingnuo, a glutathione injection counteracting toxicity and injuries from ionizing radiation. For metabolic and cardiovascular health, their offerings comprise Xuezhikang, a lipid-regulating drug for hypercholesterolaemia; Beixi, an acarbose capsule for Type 2 diabetes; and Beitangning, a pioglitazone hydrochloride capsule designed to manage blood glucose. In neurology and psychiatry, Luye Pharma provides Maitongna for cerebral edema resulting from trauma or surgery, and for venous reflux disorders. Their pipeline features the Rivastigmine Transdermal Patch for Alzheimer's disease; Fentanyl Transdermal Patch for cancer-related pain; and Buprenorphine Transdermal Patch for chronic pain. They also market Seroquel and Seroquel XR for schizophrenia and manic episodes of bipolar affective disorders, alongside Rykindo, an injectable treatment for schizophrenia. Other specialized products include Nuosen for acute upper digestive tract hemorrhage; Sailimai for the management of diarrhea; the Apleek Transdermal Patch for contraception; Sidinuo for osteoporosis; Glucosamine hydrochloride tablets for osteoarthritis; Oulai, a compound sodium aescinate gel for localized swelling; Oukai, for soft tissue swelling and venous edema; and Fengshiye, intended for patients experiencing bone, joint, and limb pain. Beyond traditional pharmaceuticals, the company also extends its operations to include the manufacturing and commercialization of biopharmaceutical products. Luye Pharma Group Ltd. was established in 1994 and is headquartered in Yantai, People's Republic of China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | -13.18% | -13.18% | -16.00% | -16.00% | +22.31% | -30.26% | -56.29% | -56.29% | -56.29% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Drug Manufacturers - General: +6.6%+1.4% Q4'25: -5.1% (vs Q4'23)
-
EPS growth Drug Manufacturers - General: +18.2%+757.1% ★ Q4'25: -27.2% (vs Q4'23)
-
FCF margin FCF growth · Drug Manufacturers - General: +36.0%+9.1% Q4'25: +13.4% (vs Q4'23)
-
EBIT margin Drug Manufacturers - General: +19.4%+19.7% ★ Q4'25: +19.4% (vs Q4'23)
-
ROIC Drug Manufacturers - General: +10.2%+4.8% Q4'25: +9.0% (vs Q4'23)
-
Share dilution Drug Manufacturers - General: +0.0%+3.6% Q4'25: +7.5% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - General: -0.29×4.64× Q4'25: 2.31× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 1 EPS Ana. |
Dec 2027 2 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2.56B
est: 3.60B (-28.8%)
|
2.92B
est: 2.85B (+2.3%)
|
3.81B
est: 3.67B (+3.9%)
|
5.17B
est: 4.91B (+5.4%)
|
6.36B
est: 6.46B (-1.7%)
|
5.54B
est: 6.44B (-14.0%)
|
5.20B
est: 5.79B (-10.1%)
|
5.98B
est: 5.33B (+12.2%)
|
6.14B
est: 6.01B (+2.3%)
|
6.06B
est: 6.53B (-7.2%)
|
6.15B
est: 6.63B (-7.4%)
|
7.16B
6.81B – 7.52B
+8.0% YoY
|
7.94B
7.28B – 8.60B
+10.8% YoY
|
8.95B
8.35B – 9.55B
+12.7% YoY
|
| EBITDA |
1.03B
est: 1.11B (-7.3%)
|
1.15B
est: 879.00M (+30.4%)
|
1.35B
est: 1.13B (+19.5%)
|
1.96B
est: 1.51B (+29.7%)
|
2.37B
est: 1.99B (+19.0%)
|
1.88B
est: 1.98B (-5.4%)
|
906.88M
est: 1.78B (-49.1%)
|
1.81B
est: 1.63B (+11.2%)
|
2.08B
est: 1.82B (+14.1%)
|
2.19B
est: 3.13B (-30.0%)
|
2.03B
est: 3.18B (-36.3%)
|
3.44B
3.27B – 3.61B
+8.0% YoY
|
3.81B
3.49B – 4.13B
+10.8% YoY
|
4.29B
4.01B – 4.58B
+12.7% YoY
|
| EBIT |
913.71M
est: 749.78M (+21.9%)
|
1.01B
est: 593.72M (+69.3%)
|
1.17B
est: 764.22M (+52.7%)
|
1.64B
est: 1.02B (+60.9%)
|
1.93B
est: 1.35B (+43.4%)
|
1.37B
est: 1.34B (+1.9%)
|
324.90M
est: 1.20B (-73.0%)
|
1.14B
est: 1.10B (+4.0%)
|
1.38B
est: 1.15B (+19.9%)
|
1.40B
est: 2.15B (-34.9%)
|
1.21B
est: 2.19B (-44.6%)
|
2.36B
2.24B – 2.48B
+8.0% YoY
|
2.62B
2.40B – 2.83B
+10.8% YoY
|
2.95B
2.75B – 3.15B
+12.7% YoY
|
| Net Income |
754.52M
est: 879.26M (-14.2%)
|
891.54M
est: 970.12M (-8.1%)
|
981.37M
est: 1.06B (-7.0%)
|
1.30B
est: 1.48B (-12.2%)
|
1.47B
est: 1.79B (-18.0%)
|
706.59M
est: 1.57B (-55.1%)
|
-144.78M
est: 841.12M (-117.2%)
|
604.81M
est: 526.74M (+14.8%)
|
532.61M
est: 600.55M (-11.3%)
|
471.89M
est: 817.85M (-42.3%)
|
602.78M
est: 623.14M (-3.3%)
|
724.19M
661.04M – 787.34M
+16.2% YoY
|
896.89M
818.67M – 975.12M
+23.8% YoY
|
1.11B
1.01B – 1.21B
+23.7% YoY
|
| SGA |
1.15B
est: 1.50B (-23.2%)
|
1.39B
est: 1.18B (+17.3%)
|
1.72B
est: 1.52B (+12.7%)
|
2.13B
est: 2.04B (+4.4%)
|
2.56B
est: 2.68B (-4.6%)
|
2.19B
est: 2.67B (-18.2%)
|
2.28B
est: 2.40B (-5.3%)
|
2.40B
est: 2.21B (+8.6%)
|
2.70B
est: 2.48B (+8.7%)
|
2.40B
est: 2.71B (-11.3%)
|
2.44B
est: 2.75B (-11.2%)
|
2.97B
2.82B – 3.12B
+8.0% YoY
|
3.29B
3.02B – 3.56B
+10.8% YoY
|
3.71B
3.46B – 3.96B
+12.7% YoY
|
| EPS |
0.23
est: 0.24 (-2.5%)
|
0.27
est: 0.26 (+3.8%)
|
0.30
est: 0.28 (+5.9%)
|
0.41
est: 0.40 (+3.0%)
|
0.46
est: 0.48 (-4.3%)
|
0.22
est: 0.42 (-47.9%)
|
-0.04
est: 0.23 (-118.6%)
|
0.17
est: 0.14 (+20.3%)
|
0.14
est: 0.16 (-12.3%)
|
0.02
est: 0.21 (-91.7%)
|
0.15
est: 0.16 (-6.2%)
|
0.19
0.17 – 0.20
+16.2% YoY
|
0.23
0.21 – 0.25
+23.8% YoY
|
0.28
0.26 – 0.31
+23.7% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-18 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Dian Bo Liu | Co-Founder, Executive Chairman, Chief Executive Officer and Head of Corporate Directions & Strategies | 481.0K | male |
| Rong Bing Yang | Co-Founder & Vice Executive Chairman | 234.4K | male |
| Yuan Yuan Zhu | Executive Director | 177.0K | female |
| Hui Xian Yuan | Co-Founder & Executive Director | 144.3K | male |
| Mei Yi Lee ACIS FCIS | Company Secretary | — | female |
| Yuan Chong Liu | Chief Financial Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for LYPHF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
